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Aim. This comparative study attempts to evaluate the profile of S-100b and Neuron-Specific Enolase (NSE), biomarkers of
brain injury, in patients undergoing carotid endarterectomy (CEA) and carotid artery stenting (CAS) and to correlate this
with haemodynamic and embolic events detected using trans-cranial Doppler (TCD).
Methods. 52 patients with internal carotid artery stenosis requiring intervention were recruited. 24 patients underwent
CAS, and 28 underwent CEA. TCD was performed peri-operatively to record mean Middle Cerebral Artery (MCA) ve-
locity and number of High Intensity Transient Signals (HITS) in the MCA of the operated side. Serum was drawn
pre-operatively and at six time points in a 48 hour post-operative period, and then assayed using automated commercial
equipment. Within and between group variability in markers were assessed by Generalized Estimation Equations
modelling.
Results. CAS caused more HITS (p¼ 0.028) but less haemodynamic disturbance (p¼ 0.0001) than CEA. Treatment mo-
dality (CAS versus CEA) had no direct effect on S-100 changes (p¼ 0.467). NSE levels declined after revascularisation in
the CAS group but not after CEA (p¼ 0.002). S-100b levels rose in patients who had higher numbers of HITS (p¼ 0.002).
S-100b and NSE were not associated with changes in MCA velocity (p> 0.5). S-100b alone increased significantly at
24 hours in those patients with a post-operative neurological deficit (p¼ 0.015).
Conclusions. Trans-cranial Doppler findings suggest that the mechanisms of rise in S-100b and NSE levels may differ
and may be due to increased peri-operative micro-embolisation and cerebral hypoperfusion respectively. Further studies
are required to assess the clinical significance of these observed changes.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The current literature provides evidence-based indica-
tions for carotid endarterectomy (CEA) in both symp-
tomatic and asymptomatic patients of low risk.1e4
Results from other important studies in process are
pending; the International Carotid Stenting Study
(ICSS) and Carotid Revascularisation Endarterectomy
versus Stent Trial (CREST) will provide the evidence
for a more valid comparison between different carotid
artery revascularization strategies.5,6 For patients
deemed ‘higher risk’, SAPPHIRE is the only random-
ized trial at the time of writing that provides clinical
data.7 However, meta-analysis of carotid angioplasty
(some without stent placement) versus CEA has
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associated with CAS and CEA are not significantly
different.8
Complication rates in terms of clinical stroke for
both procedures have fallen since their inception,
and are expected to fall further below figures recom-
mended by those bodies supervising both techniques.
As overt complication rates decline, it would be rea-
sonable to question if there is any sub-clinical morbid-
ity caused by CEA and CAS, with neurological injury
being the most pertinent.
S-100b has been shown to be a sensitive marker of
clinical and sub-clinical cerebral injury in a variety of
clinical settings ranging from traumatic head injury
and stroke, to post-operative neurological dysfunction
in cardiac surgery patients.9e11 S-100b is a cytosolic
calcium-binding protein with the ‘brain-specific’ iso-
forms ab and bb predominantly present in astroglial
and Schwann cells.12 Maximum levels of S-100b can
be detected as early as 20 minutes after brain injury,lar Surgery. Published by Elsevier Ltd. All rights reserved.
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is rapidly excreted by the kidney.13
Serum Neuron-Specific Enolase (NSE) levels have
been shown to correlate with infarct volume14 and
functional impairment after stroke.15 In cardiac sur-
gery, post-operative serum concentrations of NSE
have a predictive value with respect to early neuro-
psychological and neuropsychometric outcome after
cardiac surgery.16 NSE belongs to a family of ubiqui-
tous glycolytic enzymes occurring as series of dimeric
isoenzymes including three subunits, the a, b, and g
chains.17 The isoforms gg and ag are restricted to neu-
rons. They have a molecular weight of 78 kDa8 and
a biologic half-life in serum of 20 hours.18
There are only limited data on the release of S-100b
after CEA and CAS,19 and none on that of NSE. No
previous study has attempted to correlate changes in
the levels of these markers with potential aetiological
factors, such as peri-operative cerebral hypoperfusion
or micro-embolic phenomena.
The aims of this study are the following: firstly to
demonstrate the profile of S-100b and NSE release fol-
lowing CEA and CAS, and secondly to determine
whether intra-operative haemodynamic events, mea-
sured using Trans-Cranial Doppler (TCD), are related.
Patients and Methods
The Local Ethics Research Committee gave a favour-
able opinion for the study. All patients gave informed,
written consent prior to recruitment. Data were
collected prospectively from patients considered for
carotid revascularisation (CEA or CAS) between April
2005 and June 2006; patients were included consecu-
tively. Exclusion criteria were combined open and
endovascular surgery for revascularisation, need for
general anaesthesia, and patient refusal to participate
in the study. 40 (76.9%) patients were randomised
(using ICSS criteria), the remaining 12 (23.1%) were
selected for treatment according to patient and
surgeon’s preferences.
The degree of stenosis was determined using
duplex ultrasonography and confirmed with CT angi-
ography; the latter performed to assess patients’
anatomical suitability for CAS in all cases, and to de-
termine the degree of completeness of the circle of
Willis. No patients in this series underwent pre-
operative intra-arterial angiography.
Carotid endarterectomy
CEA was performed under loco-regional cervical an-
aesthesia (50 mL 1% lidocaine) in all cases e as isour practice wherever practicable - by one of three
Consultant vascular surgeons. Monitoring of physio-
logical parameters and consciousness was conducted
by a Consultant anaesthetist. Intra-arterial shunts
were applied selectively; the decision being made
pre-operatively (in cases where it was felt the Circle
of Willis would not maintain adequate flow) or
intra-operatively if the patient’s conscious level de-
creased. Shunts were used in 3 (10.7%) cases. Dacron
patch angioplasty of the ICA was performed in 75% of
cases. Patients remained awake during the operation
enabling active, clinical monitoring of their neurolog-
ical state. Routine physiological monitoring included
pulse oximetry, electrocardiogram, and invasive blood
pressure measurement via the radial artery. Prior
to clamping the ICA a dose of heparin (5000þ/
2000 IU e depending on body weight) was injected
intravenously.
Carotid artery stenting
CAS was also performed under local anaesthesia
(20 mL 1% lidocaine) using access via the femoral ar-
tery in all cases. In most cases an 8F guiding catheter
was used, having previously cannulated the external
carotid artery. Heparin was administered to maintain
an Activated Clotting Time (ACT) of 250e300 sec-
onds. Similar supervision of the patients’ physiologi-
cal and neurological status was performed as for the
CEA group. The procedures were performed by
a team comprising a Consultant vascular surgeon,
a Consultant radiologist, and a Consultant inter-
ventional cardiologist. Use of an Embolic Protection
Device (EPD - filter-type) and dedicated carotid stent-
ing system was universal.
Trans-Cranial doppler
On the day prior to the revascularisation procedure,
patients underwent TCD monitoring using a Doppler-
Box DWL C400 system (ScanMed Medical Instru-
ments, UK) with a 2 mHz probe. Patients were
rested at 45 degrees for a period of 15 minutes prior
to scanning. Following initial examination of the
intracerebral circulation to identify the MCA,
a frame-mounted 2 mHz probe was positioned for
the monitoring period (a standardised 30 minute pe-
riod) to insonate the first part of the MCA through
the temporal window. Emboli monitoring and MCA
velocity recording was carried out ‘on-line’ by a single
examiner. Using the recording facility on the TCD sys-
tem, ‘off-line’ analysis by a blinded examiner could
also be performed. These digitally-recorded imagesEur J Vasc Endovasc Surg Vol 34, November 2007
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pher (S.D.), with agreement in all recorded cases. A
screenshot from the system showing two emboli and
mean MCA velocity can be seen in Fig. 1.
Settings used were: depth 55(5) mm, power 5e
30 MW, and gain 5e20% to obtain the optimum dis-
play for emboli monitoring, the display of the spectral
waveform within the window was optimised for each
case, sample volume 10 mm, and a high pass filter
was set at 50 Hz. Patients were scanned continuously
for 30 minutes pre-operatively, and for the duration of
their procedure (from positioning on the operating
table through to transfer to the recovery area; CEA¼
112 24 minutes, CAS¼ 49 15 minutes).
Emboli were counted manually. Criteria for the
detection of emboli were established according to a
previously published consensus statements.20,21 Only
unidirectional High-Intensity Transient Signals
(HITS - less than 300 ms) at least 3dB higher than
that of the background signal with a characteristic
‘‘chirp’’, ‘‘snap’’ or ‘‘moan’’ were recorded as emboli.
A 3dB increase in decibel threshold was determined
visually on the colour scale. When an ‘embolic
shower’ (multiple HITS lasting longer than 1 second)
occurred, 10 emboli per second were recorded. We
acknowledge the limitations of this machine in the
detection of emboli produced during CAS: The Fast
Fourier Transform (FFT) has a time resolution of 10
milliseconds, and as such some short duration andEur J Vasc Endovasc Surg Vol 34, November 2007high frequency HITS may have been missed during
TCD monitoring.
At the time of cross-clamping or releasing the EPD
in the ICA, the decrease in mean MCA velocity was
calculated as the percent remaining velocity com-
pared with the pre-clamping velocity, allowing a brief
(10e15 s) period for cerebral autoregulation. These
data were used in analysis of the biomarker results
to further characterise and stratify the CEA and CAS
groups. We were unable to determine the nature/
composition of HITS using the software version we
had available.
Serum biomarkers of brain injury
Pre-operative samples were collected in sodium cit-
rate bottles from all patients via an arterial line
strictly adhering to the schedule shown in Table 1.
Samples taken at 48 hours were invariably taken
from a peripheral vein as per our ethically-approved
protocol.
Samples were subsequently centrifuged at 1800 rpm
for 6 minutes at 20 C and the resulting plasma stored
in multiple aliquots at 80 C; it was possible to com-
plete this process within 15 minutes of collection for all
samples as our laboratory is within 2 minutes of all
clinical areas. Prior to analysis samples were defrosted
in a water bath at 37 C, visually checked for obviousFig. 1. Typical output from TCD e note real-time, mean MCA velocity of 94 cm/s and 2 HITS confirmed by audio (white
arrows) then spectral (blue arrows) criteria.
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transferred to the automated analyser.
Serum levels of S-100b were determined using
a commercially available, automated immunolumino-
metric assay (Liason Sangtec 100, DiaSorin S.p.A,
Saluggia, Italy) with a lower detection limit of
0.02 mg/L and an upper limit of 30 mg/L. Upper limit
of normal is 0.15 mg/L in 95% of adult population.
NSE serum levels (normal upper limit 12.5 mg/L)
were measured on the same analyser, using a similar
methodology. The biochemist (R.S.) responsible for
performing these analyses was blinded to the treat-
ment group and TCD data.
Statistical analysis
Continuous variables were expressed as mean SD.
P-values 0.05 were considered statistically significant.
Comparisons of demographics, risk factors and TCD
data between treatment groups were made using the
t-test. Changes S-100b and NSE over time were consid-
ered as repeated measures data and analyzed by using
Generalized Estimating Equations (GEE).22,23 Mar-
ginal models (autoregressive matrix) based on general-
ised estimation equations were used to perform
regression analysis. Our analysis took into account
the fact that modelling the variation in markers of brain
injury (S-100b and NSE) should be based primarily in
subjects (within variation) rather than between differ-
ent groups (between variation).
Regression analysis
We developed a GEE model and performed a multi-
variate regression analysis. The following variables
were included: type of intervention (CEA or CAS),
serum creatinine levels (only used in analysis of
S-100b - which is cleared by the kidney), presence of
a post-operative neurological deficit, timing of sam-
ple, high or low rates of embolisation (high>median
number of HITS (58), low 58 HITS), and high or low
drop in MCA velocity (high¼MCA velocity drop >
median (5%) from baseline, low¼MCA velocity
drop 5% from baseline).
Table 1. Schedule for blood sampling in both groups
Sampling Point Operative Step
1 Pre-operatively in theatre
2 5 minutes post declamp/EPD retrieval
3 6 hours post operatively
4 12 hours post operatively
5 24 hours post operatively
6 >48 hours post operatively (if hospitalised)Analysis was conducted by using the statistical
software Intercooled Stata version 9.2 for Windows
(Stata Corporation, USA) and SPSS version 15.0 for
Windows (SPSS Inc, Chicago, IL, USA).
Results
Descriptive results of study population
52 patients undergoing elective procedures were en-
tered into this study (CEA¼ 28, CAS¼ 24). There
were no statistical differences in terms of pre-operative
symptom-status, or degree of stenosis (Table 2). There
was a stronger history of IHD in the CAS group: this
is to be expected through surgeon selection bias e
CAS is most beneficial in reducing peri-operative MI
risk. CAS was also performed in patients with
a greater contralateral ICA stenosis, reflecting the in-
clusion of 2 patients with occluded contralateral ves-
sels undergoing CAS prior to CABG (to safeguard
their brain during periods of intra-operative
hypotension).
Of those undergoing CEA, 2 (7.1%) patients had
post-operative cranial nerve lesions (temporary) and
3 (10.7%) had clinically-apparent neurological deficits
in the immediate (<24 h) post-operative period. There
was one case of facial weakness (Modified Rankin
Score24 1), one case of transient arm weakness (MRS 1),
and one case of transient hemiparesis (MRS 3, but
resolved completely). There were no new infarcts
localised on post-operative CT imaging of the brain.
There was no mortality at 30 days.
3 (13%) of those patients who underwent CAS had
complications. 2 (8.7%) had haematomas at access
sites (they did not require surgical exploration/re-
pair), and 1 (4.3%) suffered a permanent ocular stroke
on the operated side. No mortality was observed in
the 30-day post-operative period, but two patients
died before outpatient follow-up at 6 weeks: One
from complications of valvular heart surgery, and
the other from an acute myocardial infarction at
home.
Trans-Cranial doppler studies
A trans-cranial ultrasonic window allowed capture of
data in 20 (71.4%) of patients undergoing CEA and 18
(75.0%) of the patients who had CAS. This relatively
low capture rate a result of either the patient having
no acoustic window (9 patients - 17%) or the TCD re-
source not being available (6 cases - 11%). CEA was
associated with a greater fall in MCA velocity
(25.5% Vs þ2.7%, p< 0.0001) when comparing theEur J Vasc Endovasc Surg Vol 34, November 2007
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Variable Carotid Endarterectomy Carotid Artery Stenting p value
N¼ 28 % N¼ 24 %
Age (years) 67.2 15.6 e 62.8 19.3 e ns
Male gender 17 60.7 20 83.3 ns
Symptomatic 19 67.9 10 41.6 ns
Asymptomatic 9 32.1 14 58.4 ns
Ipsilateral stenosis (%)* 79.4 e 82.0 e ns
Contralateral stenosis (%)* 40.6 e 57.5 e p¼ 0.034
History of hypertension 25 89.3 21 87.5 ns
History of smoking 16 57.1 18 75.0 ns
History of dyslipidaemia 23 82.1 24 100 ns
History of diabetes mellitus (IDDM or NIDDM) 7 25 7 29.2 ns
History of IHD (Previous angina/MI/CABG/PCI) 10 35.7 19 79.2 P< 0.05
Renal impairment 4 14.3 5 20.8 ns
COAD 6 21.4 8 33.3 ns
* Defined using Duplex scanning and ECST criteria.period of ICA cross-clamping and the period that the
EPD was deployed (Fig. 2). The duration of this inter-
ruption to normal flow in the operated ICA was also
greater in the CEA group (41.5 minutes Vs 17.5 min-
utes, p< 0.0001) and this is demonstrated in Fig. 3.
There was excellent inter-observer reliability
(R2¼ 0.98, p< 0.01), as demonstrated in Fig. 4. A
mean of both observers’ results was used to compare
the incidence of HITS in both groups. We noted that
CAS produced a significantly higher number of sig-
nals than CEA (239 Vs 42, p¼ 0.028) and this is shown
in Fig. 5.
Serum biomarkers of brain injury
Baseline S-100b levels were 2e3 times higher than that
of a normal population: Mean levels in the CEA group
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Fig. 2. Changes in mean MCA velocity (expressed as per
cent change from pre-clamp/pre-EPD deployment values)
for both groups.Eur J Vasc Endovasc Surg Vol 34, November 2007were 0.32 ng/mL (0.33) and in the CAS group
0.52 ng/mL (0.85). After intervention there was
a non-significant trend of transient rise of S-100b
levels in the group that underwent treatment with
CAS: Levels in the CEA group appear unchanged.
These results are shown in Fig. 6.
Baseline NSE levels were the same for each group
(but at levels six times that of a normal population),
and appeared to rise at 48 hours post-operatively in
the CEA group, and decline in the CAS group. No sta-
tistically significant differences occurred between the
treatment groups at any time point,e see Fig. 7.
Regression analysis
The results of these analyses are shown in Table 3.
Changes in S-100b were not due to an effect of CAS
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Fig. 3. Differences in duration of ICA cross-clamp and EPD
deployment.
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Eur J Vasc Endovasc Surg Vol 34, November 2007versus CEA as a treatment modality for ICA stenosis
(p¼ 0.467). CAS was responsible for a significant de-
crease in post-operative NSE levels when compared
with CEA, (p¼ 0.002). Higher rates of embolisation
were significantly implicated in changes of S-100b
(p¼ 0.002), but not NSE (p> 0.05).
We saw no significant differences in S-100b levels
in the groups that did or did not have drops in in-
tra-operative MCA velocity, and within our models
differences in NSE were not associated with changes
in MCA velocity as measured using TCD (p> 0.3 in
both instances).
In the group of patients that developed post-opera-
tive neurological complications there was a significant
rise in S-100b levels compared to pre-operative levels
(p¼ 0.015), but this was not complemented by a simi-
lar change in expression of NSE (p¼ 0.467).
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Fig. 4. Inter-observer reliability between real-time and off-
line analysis of HITS was excellent.
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Fig. 5. Differences in the number of HITS recorded in each
treatment group.Discussion
Our data strongly suggest that the number of HITS
detected using TCD during carotid revascularisation
is related to the observed changes in levels of
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Fig. 6. Changes in S-100b for each treatment group over
time. Note the non-significant increase in mean concentra-
tions for the CAS group at the post-EPD retrieval and
6 hour time points.
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Fig. 7. There was a trend for NSE serum levels to decline af-
ter treatment in the CAS group, and rise in the CEA group.
558 R. E. Brightwell et al.Table 3. Results of GEE using models for both S-100b and NSE
b-coefficient Standard error p-value 95% CI
S-100b
Effect of CAS Vs CEA 0.067 0.092 0.467 0.25 to 0.11
Creatinine 0.001 0.001 0.472 0.09 to 0.37
Timing of sample 0.054 0.054 0.008 0.01 to 0.09
Post-op deficit 0.182 0.074 0.015 0.04 to 0.33
MCA Velocity Drop 1.023 8.345 0.324 26.56 to 18.43
HITS 0.231 0.073 0.002 0.09 to 0.37
Constant 0.057 0.127 0.655 0.19 to 0.31
NSE
Effect of CAS Vs CEA 34.429 11.249 0.002 56.48 to 12.38
Timing of Sample 4.537 2.319 0.050 0.01 to 9.08
Post-op deficit 6.686 9.183 0.467 11.31 to 24.68
MCA velocity drop 2.439 10.299 0.813 22.63 to 17.75
HITS 0.187 12.911 0.654 0.12 to 2.12
Constant 56.953 20.610 0.006 16.56 to 97.35S-100b; a serum marker of brain injury that has been
shown to correlate with long-term neurological out-
come after cardiac surgery.11 Our observations have
shown CAS is associated with higher numbers of
peri-operative HITS than CEA (despite using a cere-
bral protection device routinely) but we were unable
to show any statistically significant changes in S-100b
when comparing both treatment groups. It is however
important to note a non-statistically significant trend
for mean S-100b concentrations in patients undergo-
ing CAS to increase, while mean levels remained
static throughout the measured time course in those
undergoing CEA. This finding is contradictory to the
results of the one previously published study that
compared S-100b levels in only 14 cases of CAS, and
28 of CEA.19 There are two possible explanations:
Firstly in the latter series patients routinely received
a general anaesthetic (GA) for CEA which could be
a confounding factor, and secondly the statistical
methodology used to assess repeated measures in
this instance was, however, less sensitive than that
employed in our study.
It has been previously hypothesised that the rise in
S-100b observed in patients undergoing CEA is due to
a transient impairment of the blood-brain barrier, or
even represents sub-clinical neurological injury asso-
ciated with brain cell death. The postulated aetiology
of this ‘injury’ is hemispheric hypoperfusion, leading
to global ischaemia. The findings from our TCD stud-
ies have confirmed that CEA generates more flow dis-
turbance (in terms of MCA velocity reduction) than
CAS. During CAS hypoperfusion is limited by the
use of an EPD that allows continuous antegrade
flow of blood in the operated ICA. Also, the use of
a balloon (that occludes flow in the ICA) to perform
a pre-dilatation angioplasty or expand a stent is tem-
porary, lasting 5e10 seconds.Eur J Vasc Endovasc Surg Vol 34, November 2007It is also important to identify the reasons why we
observe an S-100b rise in the CAS group. There are sev-
eral explanations for this: Firstly, an increased number
of HITS (and thus assumed embolic phenomena)
observed during carotid revascularisation is poten-
tially more injurious (in terms of S-100b increase
only) than a period of relative hypoperfusion, espe-
cially if patients have been ‘preconditioned’ to hypo-
perfusion by having a haemodynamically significant
ICA stenosis and/or a previous ischaemic injury to
the brain (i.e. TIA or stroke); this argument can be
strengthened by our observation of higher levels of
S-100b in the group with greater levels of embolisa-
tion. Secondly, by using awake neurological monitor-
ing during CEA we have been able to place a shunt in
those patients who may otherwise have had an S-100b
rise without a recognisable physiological response
suggestive of brain ischaemia (e.g. hypertension after
ICA cross-clamping). Finally, other factors should be
considered, but are difficult to investigate: Complete-
ness of the Circle of Willis (CoW), plus the degree of
external-internal carotid communication/collaterali-
sation must be important and both warrant further
investigation.
Levels of NSE behaved differently; it was not re-
lated to TCD-detected changes in MCA velocity, num-
ber of detected HITS, nor post-operative neurological
deficit. Instead we noted the significant effect of NSE
levels declining after revascularisation, but less so af-
ter CEA compared with CAS. This trend has been pre-
viously described before by Rasmussen et al. who
noted that patients undergoing CEA had higher pre-
operative levels of NSE than a control group (matched
for age and risk factors but without significant, con-
current ICA stenosis) undergoing abdominal aortic
aneurysm (AAA) repair, and that after treatment
NSE levels lowered post-operatively to the level
559Brain Injury Markers in Carotid Revascularisationobserved in the AAA group.25 We currently have no
robust explanation for this observation, but we may
hypothesise that a significant ICA stenosis causes
a higher background level of NSE release, and on
overcoming such haemodynamically significant le-
sions brain perfusion is normalised and these levels
subsequently fall with time. Of note, we observed
a non-significant trend for pre-operative NSE levels
to be higher in patients with greater degrees of bilat-
eral ICA stenosis and to rise in patients who had
very large drops in their MCA velocity during their
revascularisation procedure (i.e. those who under-
went ICA cross-clamping and had a deficient CoW).
This raises important questions as to the aetiology of
injury (e.g. embolisation versus global ischaemia, or
a combination of both) that causes NSE, and indeed
S-100b, to be released.
We observed high pre-operative levels of S-100b in
both treatment groups, with highest levels in the
CAS group particularly. This overall observation
could be representative of the number of recently
symptomatic (and therefore recently brain injured)
patients in our study population, but we cannot
explain the disparity in baseline levels of S-100b
between treatment groups. We also noted that those
patients who produced a greater number of HITS
(thus emboli) during their procedure had higher base-
line levels if S-100b than those that did not.
3 patients suffered from a neurological deficit after
CEA and one suffered an ocular stroke after CAS. The
peak concentration of S-100b occurred near 24 hours
after injury and this is in keeping with other studies
looking at its release in patients with such deficits
and validates our results: Sustained elevated S-100b
levels correlate with neurological complications, and
the amount released tends to reflect the extent of
ischaemic damage to astro-glial cells.26
Study limitations
Potential criticisms of the study could include that the
samples taken within the first 24 hours were from an
arterial line, and subsequent samples from a venous
site. While small differences in S-100b serum levels
in samples taken simultaneously from the radial ar-
tery and a jugular line has been shown, others have
shown no difference.27 We must also accept that the
study population was not fully randomised and that
surgeon/patient choice may have created a selection
bias: fortunately, however, this did not cause signifi-
cant differences when comparing the degree of steno-
sis and comorbidity between treatment groups.
Continuing TCD monitoring in the post-operativeperiod for a period longer than 15 minutes would
also have been beneficial, since many HITS may
have occurred undetected during this period. Finally
a more sensitive marker of renal function and impair-
ment, such as Cystatin-C, may have shown differ-
ences between each treatment group and impacted
more on subsequent regression analyses.
Our group continues to study the sub-clinical neu-
rological effects of CEA and CAS using other outcome
measures including neuropsychometric testing, high-
resolution neuro-imaging techniques, and novel se-
rum markers of brain injury. We are also studying
the effects of degrees of completeness of the CoW,
and extent of extra-intra cerebral collateralisation on
such outcomes.
In determining the clinical relevance of these
findings by using such morphological and functional
techniques we hope to be able to better predict which
patients are at risk of clinical and sub-clinical neurolog-
ical injury, and to be able to decide whether open or
endovascular treatment is safer on a patient-to-patient
basis. This will allow us to offer a more individualized
option for the management of atherosclerotic ICA
stenosis (e.g. CEA or CAS, type of EPD and stent, pro-
phylactic shunt) and thus improve patient safety and
outcome.
Conclusions
The present study suggests that an increased inci-
dence of HITS during carotid revascularisation may
be responsible for either a transient defect in BBB
function, or cause actual brain cell damage/death.
This is despite routine use of an EPD that allows con-
tinuous antegrade blood flow routinely for CAS, and
awake monitoring during CEA. Although embolisa-
tion appears to be more frequent during CAS, more
clinical neurological complications occurred in the
group undergoing CEA, in whom we saw greater
MCA flow disturbance. This raises the question of
the clinical significance of transient rises in S-100b
and NSE, such as that measured in most of the pa-
tients we studied, and is the subject of further investi-
gation by our group.
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